1 Click Subscribe to the RSS feed
1 click ADD to your Google HomepageCadherins and Looming Revolution in Cancer Treatment ( Adherex )
A little known but critical technical advance in the treatment / shrinkage of solid tumors is currently in development by a very small but very talented firm that is the merger of a McGill university spinoff and a firm ( Oxiquant ) founded by more experienced cancer treatment physicians.
Adherex Technology, originally from McGill has been working on its methods for applying cell adhesion compounds to safe and selective destruction of tumor vasculature.
Where is the significance one might ask? Plenty and it is not "run of the mill me too"....
CLICK READ MORE... for rest of article.
A rare drug candidate that has exceptional tumor selectivity, fast acting 30 minute basic effect on the particular ( n-cadherin ) marked soft tissue tumors, and what appears to be no upper dose limit to onset of toxicity found ( the ADH-1 compound is normally made in small amounts by the body ), and the compound is safely metabolized quickly in 4 hours with no traces found therafter.
Susceptible n-cadherin marked tumors can exhibit onset of safe tumor necrosis in 30 minutes of the ADH-1 compound being administered.
Sorry there is little press on the firm, but this comes from the fact that in Canada most of the press online is by subscriber only and archives are accessable only for fee and not google indexed.
As a result, few know about this looming revolution in cancer therapy, that is going to take the world by storm in a few years as it progresses through FDA trials. ( currently completed Phase 1 and into Phase 1B / 2 concurrently ) Phase 1 showed both tumor shrinkage and no side effects what so ever )
Besides this novel ADH-1 chemistry, Adherex is also engaged in developing an improvement to the chemotherapy agent 5FU to increase the probability of being orally adminstered, and improve patient endpoints, and reduce side effects, after eyeing a failure in Glaxo's efforts to do the same, and seeing where they could remedy the percieved errors in prior implementations.
Key technologists include Adherex co-founder Prof. Orest Blaschuk of McGill Urology and Dr. William Peters, president of Adherex.
Watch for this one.
[ed - more of Adherex posts are linked just below]
wendman nano nanotech cadherin orest+blaschuk blaschuk blaschuk+mcgill mcgill+urology mcgill+adherex adherex adherex+peters peters+william robin+norris adh1 adh-1 exherin n-cadherin e-cadherin n-cadherin+antagonist nanotechnology cancer+pharmaceuticals safe+cancer+drug angiostatin avastin tumor+necrosis cancer+cure
Adherex Technology, originally from McGill has been working on its methods for applying cell adhesion compounds to safe and selective destruction of tumor vasculature.
Where is the significance one might ask? Plenty and it is not "run of the mill me too"....
CLICK READ MORE... for rest of article.
A rare drug candidate that has exceptional tumor selectivity, fast acting 30 minute basic effect on the particular ( n-cadherin ) marked soft tissue tumors, and what appears to be no upper dose limit to onset of toxicity found ( the ADH-1 compound is normally made in small amounts by the body ), and the compound is safely metabolized quickly in 4 hours with no traces found therafter.
Susceptible n-cadherin marked tumors can exhibit onset of safe tumor necrosis in 30 minutes of the ADH-1 compound being administered.
Sorry there is little press on the firm, but this comes from the fact that in Canada most of the press online is by subscriber only and archives are accessable only for fee and not google indexed.
As a result, few know about this looming revolution in cancer therapy, that is going to take the world by storm in a few years as it progresses through FDA trials. ( currently completed Phase 1 and into Phase 1B / 2 concurrently ) Phase 1 showed both tumor shrinkage and no side effects what so ever )
Besides this novel ADH-1 chemistry, Adherex is also engaged in developing an improvement to the chemotherapy agent 5FU to increase the probability of being orally adminstered, and improve patient endpoints, and reduce side effects, after eyeing a failure in Glaxo's efforts to do the same, and seeing where they could remedy the percieved errors in prior implementations.
Key technologists include Adherex co-founder Prof. Orest Blaschuk of McGill Urology and Dr. William Peters, president of Adherex.
Watch for this one.
[ed - more of Adherex posts are linked just below]
adherex-phase-1-ADH-1_Combo-clinical-trial-announcement
adherex-receives-regulatory-approval-for-dosing-increase
http://finance.yahoo.com/q?s=ADH&d=t on AMEX and
http://finance.yahoo.com/q?s=AHX.TO&d=t on toronto
wendman nano nanotech cadherin orest+blaschuk blaschuk blaschuk+mcgill mcgill+urology mcgill+adherex adherex adherex+peters peters+william robin+norris adh1 adh-1 exherin n-cadherin e-cadherin n-cadherin+antagonist nanotechnology cancer+pharmaceuticals safe+cancer+drug angiostatin avastin tumor+necrosis cancer+cure
posted by Mark Wendman at 6:35 AM
0 Comments:
Post a Comment
<< Home